GenomeKey enables targeted Sepsis treatment in hours, rather than days. This is important because Sepsis now kills more people than cancer. It can hit anyone, of any age, and kills within hours. A patient admitted to a hospital today, they wait 3 days before the doctor knows which antibiotic will fight the infection. We use cutting edge machine learning and DNA sequencing to bring 3 days down to just a few hours, with the only affordable test that provides a result for every patient. This saves lives, saves money, and saves our last antibiotics for when we really need them.
| Website | https://genomekey.com |
| Employees | 35 (31 on RocketReach) |
| Founded | 2019 |
| Technologies |
JavaScript
,
HTML
,
G Suite
+5 more
(view full list)
|
| Industry | Biotechnology |
| Keywords | Sepsis Treatment, Critical Care Diagnostics, Infection Diagnostics, Hospital Diagnostics, Genomic Diagnostics, Sepsis Prevention, Infectious Disease Diagnostics, Point-Of-Care Diagnostics, Patient Diagnostics, Healthcare Diagnostics, Medical Diagnostics |
| Competitors | Illumina, Thermo Fisher Scientific, QIAGEN, BGI Genomics, Roche, PacBio, Genomics England, 10x Genomics, Agilent Technologies, Zymergen, Inc. +43 more (view full list) |
Looking for a particular GenomeKey employee's phone or email?
Michael Roberts is the Co-Founder and CEO of GenomeKey.
31 people are employed at GenomeKey.
GenomeKey is based in Bristol, England.